Pollenallergie gegen Gräser- und Roggenpollen,Allergentablette,Dieser Newsletter des Info-Netzwerk Medizin 2000 publiziert aktuelle Neuigkeiten zur Diagnostik und Therapie allergischer Erkrankungen

Pollenallergie und subliguale Immuntherapie (SLIT): An der Universitätsklinik Köln wurden 105 unter einer Allergie gegen Gräser- und Roggenpollen leidende Patienten mit einer sublingual anzuwendenden standardisierten Allergen-Tablette behandelt. Es zeigte sich, dass diese Therapie sicher war und außerdem die Heuschnupfen-Symptome deutlich abmilderte. Die bei der entsprechenden Diagnostik zu beobachtenden Hautsymptome wurden durch die Tabletten-Therapie auch
abgemildert. (6)

Eine vollständige englischsprachige Kurzversion dieser Studie
(sog. MEDLINE Abstract) finden Sie hier

Autor(en):	Mösges R, Brüning H, Hessler HJ, Götz G, Knaussmann HG
Titel:	Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial.
Journal:	Acta Dermatovenerol Alp Panonica Adriat. 2007 Dec; 16(4): 143-8.
Bezug:	IMSIE - Klinikum der Universität zu Köln, D-50924 Cologne, Germany. ralph@moesges.de

Abstract:

BACKGROUND: Sublingual immunotherapy (SLIT) is a recognized and safe treatment for allergic rhinitis and conjunctivitis. The aim was to evaluate the efficacy and safety of tablets for grass and rye pollen- induced rhinitis and conjunctivitis.

METHODS: A double-blind, randomized, placebo-controlled trial was carried out over 9 months. 105 patients received a standardized grass/rye mix extract or a placebo using sublingual drops during the build-up phase. Drops were replaced by sublingual tablets during the maintenance phase (300 IR/daily).

RESULTS: In patients that received active treatment, a significantly lower total symptom score (rhinitis and conjunctivitis) compared to the placebo group was observed (p = 0.038). The investigators' assessment revealed a significant improvement in favor of the active treatment group (p = 0.018). Skin reactivity to grass and rye pollen was significantly reduced in the active treatment group (p < 0.05). No statistical difference was observed between the two groups for serum-specific IgG4 levels. Side effects were local and mild, and no severe systemic reactions were reported.

CONCLUSION: This study indicates that tablet-based sublingual immunotherapy was safe and significantly improved grass/rye pollen-induced rhinoconjunctivitis symptoms. It was also associated with a significant inhibition of the immediate skin response.